While the weight-reducing effects of GLP-1 agonists are well documented in metabolic disorders, there are limited data regarding their use in managing endocrine therapy-associated weight gain
During low-intensity aerobic exercise, the body prefers to use fatty acids as the main energy source, and an adequate supply of carnitine can promote FAO and support prolonged exercise [275]
For women without a GERD history, new-onset reflux during GLP-1 treatment is typically transient and manageable with the right adjustments
Under pancreatic cancer conditions, micro-RNAs (miRNAs) secreted from PDA activate PI3K/Akt/FoxO1 signal pathway to suppress myotube cells response to insulin in muscle tissue (Wang et al., 2017)
So are GLP-1 medications that treat obesity and type 2 diabetes (among other diseases)
This risk is particularly significant given the documented intrinsic antibiotic resistance profiles of numerous Lactobacillus species, which demonstrate natural resistance to vancomycin, tetracycline, chloramphenicol, and erythromycin